Immunotherapy in endometrial cancer: rationale, practice and perspectives

Biomarker Research

Chenggong Sun¹  Qing Zhang¹  Beihua Kong¹  Xinyue Ma¹  Wenyu Cao¹  Jean Victoria Fischer² 

[1] Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 West Wenhua Road, 250012, Ji’nan, Shandong, P.R. China;Gynecology Oncology Key Laboratory, Qilu Hospital, Shandong University, 250012, Ji’nan, Shandong, P.R. China;Department of Pathology, Northwestern Medicine, Gynecologic Pathology Fellow, Chicago, Illinois, USA;

关键词: Endometrial cancer;    Immunotherapy;    Biomarkers;    Immune checkpoint blockades (ICBs);    Vaccine;    ACT, MetS, p53 mutant;    Hormone aberrations;   

DOI  :  10.1186/s40364-021-00301-z

来源: Springer

【 摘 要 】

Tumor immunotherapy has attracted more and more attention nowadays, and multiple clinical trials have confirmed its effect in a variety of solid tumors. Immune checkpoint inhibitors (ICIs), cancer vaccines, adoptive cell transfer (ACT), and lymphocyte-promoting cytokines are the main immunotherapy methods. Endometrial cancer (EC) is one of the most frequent tumors in women and the prognosis of recurrent or metastatic EC is poor. Since molecular classification has been applied to EC, immunotherapy for different EC subtypes (especially POLE and MSI-H) has gradually attracted attention. In this review, we focus on the expression and molecular basis of the main biomarkers in the immunotherapy of EC firstly, as well as their clinical application significance and limitations. Blocking tumor immune checkpoints is one of the most effective strategies for cancer treatment in recent years, and has now become the focus in the field of tumor research and treatment. We summarized clinical date of planned and ongoing clinical trials and introduced other common immunotherapy methods in EC, such as cancer vaccine and ACT. Hormone aberrations, metabolic syndrome (MetS) and p53 mutant and that affect the immunotherapy of endometrial cancer will also be discussed in this review.

【 授权许可】

CC BY